阿迪波涅丁基因多态性:对它们在晚发性阿尔茨海默病风险中的作用的病例对照研究
Juraj Javor1, Vladimíra Ďurmanová1, Kristína Klučková2
1Institute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Life (Basel, Switzerland)
|March 28, 2024
概括
在斯洛伐克高加索人群中,ADIPOQ基因的遗传变异与晚发性阿尔茨海默病 (LOAD) 风险没有显著的关联. 然而,特定的ADIPOQ变异与血腺素水平的改变有关.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
背景情况:
- 脂肪组织分泌的激素阿迪波涅丁 (Adiponectin) 影响了新陈代谢的恒常性.
- 新出现的证据表明,阿迪波内克在晚发性阿尔茨海默病 (LOAD) 病原发生过程中的潜在作用.
研究的目的:
- 研究ADIPOQ基因变异,血腺素水平和LOAD风险之间的关联.
- 在斯洛伐克的高加索人群中分析ADIPOQ基因中的单核酸多态 (SNPs).
主要方法:
- 在385名LOAD患者和533名对照中对18个ADIPOQSNP进行基因型定型.
- 逻辑回归用于LOAD风险关联和线性回归用于阿迪波内克丁水平.
- 基于性别和APOE ε4等位基的分层分析.
主要成果:
- ADIPOQ 变异 rs822395 和 rs2036373 与总脂蛋白水平升高有显著关联.
- 在任何ADIPOQSNP和LOAD风险之间没有发现显著的关联.
- 对性别和APOE ε4状态的亚组分析没有显示任何与LOAD风险的显著关联.
结论:
- 虽然阿迪波涅丁可能在LOAD中发挥作用,但这项研究发现ADIPOQ基因变异和LOAD易感性之间没有显著的关联.
- 特定的ADIPOQ变体会影响皮质素水平,但似乎不会在这个人群中产生晚发性阿尔茨海默病的风险.
更多相关视频
相关概念视频
Human Genetics
566
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
566
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K


